Titre : | Much ado about dosing: The needs and challenges of defining a standardized cannabis unit (2021) |
Auteurs : | S. JUGL ; R. SAJDEYA ; E. J. MORRIS ; A. J. GOODIN ; J. D. BROWN |
Type de document : | Article : Périodique |
Dans : | Medical Cannabis and Cannabinoids (Vol.4, n°2, December 2021) |
Article en page(s) : | 66-78 |
Langues: | Anglais |
Discipline : | PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods) |
Mots-clés : |
Thésaurus mots-clés CANNABIS ; CANNABIDIOL ; CANNABINOIDES ; PHARMACOCINETIQUE ; REPERE DE CONSOMMATION |
Résumé : |
Key Points:
A definition of a standardized cannabis unit is needed to accelerate research in medical cannabis and enable safe and effective use of medical cannabis products. A standardized cannabis unit should incorporate several factors, such as plant-related aspects (e.g., varied cannabinoid concentrations in Cannabis sativa) and product attributes, such as different administration routes and cannibinoid concentrations. Furthermore, different intentions for the use and desired subjective effects also influence the dose needed for the intended effect. Many barriers remain in defining a standardized unit for cannabis (e.g., different delivered doses and pharmacokinetics depending on the administration route) and pathophysiological factors that can impact the response to the therapy or side-effect profile. A recent proposal for a standardized tetrahydrocannabinol (THC) unit by Freeman and Lorenzetti, which defines a "Standard THC Unit" of 5 mg THC, presents a sophisticated approach to support safe, nonmedical cannabis consumption within the same administration route. However, this approach may be limited when considering medical cannabis products, given a need to track efficacy and safety, a variety of products available, and the need to understand the composition of other cannabinoids. Further efforts in developing a standardized cannabis unit are needed to capture the medical cannabis perspective, possibly including the antagonizing effect of cannabidiol on THC, the role of the entourage effect, and the relationship between pharmacokinetic profiles and therapeutic effects of cannabis constituents. |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 20 |
Affiliation : | Consortium for Medical Marijuana Clinical Outcomes Research, University of Florida, Gainesville, FL, USA |
Lien : | https://doi.org/10.1159/000517154 |
Accueil